Scarica l'app Stockscreener
58.30
2.53%
1.44
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
U.S. Batten disease experts who lobbied B.C. to reinstate drug had relationships with company - Times Colonist
BioMarin’s SWOT analysis: rare disease specialist’s stock faces competition, pipeline potential - Investing.com
Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo Finance
Phenylketonuria Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharma - Barchart.com
BC consulted U.S. Batten disease experts who had links to drug company - Vancouver Sun
Solid Earnings Reflect BioMarin Pharmaceutical's (NASDAQ:BMRN) Strength As A Business - Yahoo Finance
Can Traders Expect Breakout From BioMarin Pharmaceutical Inc. This WeekJuly 2025 Setups & Stock Timing and Entry Methods - beatles.ru
BioMarin Announces Resignation of Chief Accounting Officer - The Globe and Mail
Skeletal Dysplasia Market Growth Analysis 2025-2030 - GlobeNewswire
Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Leerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105 - Insider Monkey
Refocused, deal-hungry drugmaker BioMarin pushes toward $4 billion revenue target - The Business Journals
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Positive Earnings Growth Hasn't Been Enough to Get BioMarin Pharmaceutical (NASDAQ:BMRN) Shareholders a Favorable Return Over the Last Five Years - 富途牛牛
BioMarin Pharmaceutical Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2025 Earnings Call Transcript - Insider Monkey
BioMarin Pharmaceutical (BMRN) Receives a Buy from Stifel Nicolaus - The Globe and Mail
Biomarin Pharmaceutical shares rise 2.68% premarket after UBS raised its price target to $114. - AInvest
BioMarin Pharmaceutical Inc. Reports Strong Q2 2025 Results - The Globe and Mail
BioMarin’s Earnings Call: Growth Amid Challenges - TipRanks
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401 (NASDAQ:BMRN) - Seeking Alpha
Research Alert: CFRA Keeps Buy View On Shares Of Biomarin Pharmaceutical Inc. - 富途牛牛
BIOMARIN PHARMACEUTICAL INC SEC 10-Q Report - TradingView
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030 - inkl
BioMarin stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com
BMRN Makes Bullish Cross Above Critical Moving Average - Nasdaq
BioMarin touts promising early result for potential Voxzogo successor - Fierce Pharma
UBS Adjusts Price Target on BioMarin Pharmaceutical to $114 From $113, Maintains Buy Rating - MarketScreener
BioMarin Axes Pre-Clinical PKU Drug, Citing Underwhelming Immunogenicity - BioSpace
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View - Yahoo Finance
Morgan Stanley Raises Price Target on BioMarin Pharmaceutical to $104 From $96, Keeps Overweight Rating - MarketScreener
BioMarin raises 2025 full-year guidance with $3.125B revenue target and advances BMN 333 - MSN
BioMarin: Q2 Earnings Snapshot - New Haven Register
BioMarin Pharmaceutical Inc (BMRN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
BioMarin’s Earnings Beat Forecasts And Hike Guidance For 2025 - Finimize
BioMarin Pharmaceutical Q2 2025 Earnings Call Transcript - MarketBeat
BioMarin (BMRN) Q2 Revenue Jumps 16% - The Motley Fool
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Earnings call transcript: Biomarin beats Q2 2025 estimates, stock rises By Investing.com - Investing.com Canada
Earnings call transcript: Biomarin beats Q2 2025 estimates, stock rises - Investing.com
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
BioMarin Pharmaceutical Reports Strong Q2 EarningsNews and Statistics - IndexBox
Biomarin Pharmaceutical Inc. Bottom Line Rises In Q2 - Nasdaq
BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Strong Q2 Numbers, Stock Soars - TradingView
BioMarin Pharmaceutical Q2 Non-GAAP EPS, Revenue Increase; Shares Rise After Hours - MarketScreener
BioMarin Pharma Q2 revenue beats estimates - MarketScreener
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Reports Q2 Revenue $825.0M, vs. FactSet Est of $761.7M - MarketScreener
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q2 Adjusted EPS $1.44 per Share, vs. FactSet Est of $0.82 - MarketScreener
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):